Fig. 6.

DGKζ deficiency increases the anti-tumor capacity of IL-2-differentiated CD8⁺ cells.

a. Carttoon shows how experiments were performed: BALB/c WT mice received subcutaneous injections of 10⁷ A20 cells. After eight days, mice were randomly divided in two groups IL-2-differentiated BALB/c WT or DGK^−/− cells (8 × 10⁵) were injected intratumorally, and tumor progression was evaluated daily until complete tumor regression. b. Percentage of tumor-free mice on days post-injection of cytokine-treated cells. Gehan-Breslow-Wilcoxon test; n = 14/genotype in three independent experiments. c. Tumor volume at day 8 was divided by the number of days on which the same tumor was no longer palpable. Mann-Whitney test.